Structured residency programmes within dedicated associations of hospitals, practices and medical care centres offer the opportunity to improve the quality of training and to increase the attractiveness of urology through fixed rotations of doctors in continued training. The implementation of such programmes is guided by the framework conditions of the respective location. Possible rotations range from andrology to paediatric urology and uro-gynaecology to interdisciplinary uro-oncology. An outpatient training period also offers the chance for a change of perspective and supports career orientation. Rotations in the interdisciplinary intermediate care unit offer the opportunity to become familiar with the care of complex disease processes, including the differential diagnostic assessment of abdominal diseases, which is important in urology. In summary, the diversity of urological training available can enable junior urologists to receive more individualised and targeted training by promoting multilayered, intersectoral as well as interprofessional training.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00120-022-01879-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Emerging Technologies for Multiphoton Writing and Reading of Polymeric Architectures for Biomedical Applications.
Annu Rev Biomed Eng
January 2025
1School of Engineering, Brown University, Providence, Rhode Island, USA;
The rise in popularity of two-photon polymerization (TPP) as an additive manufacturing technique has impacted many areas of science and engineering, particularly those related to biomedical applications. Compared with other fabrication methods used for biomedical applications, TPP offers 3D, nanometer-scale fabrication dexterity (free-form). Moreover, the existence of turnkey commercial systems has increased accessibility.
View Article and Find Full Text PDFValue Propositions for Digital Shared Medication Plans to Boost Patient-Health Care Professional Partnerships: Co-Design Study.
J Particip Med
January 2025
Department of Ambulatory Care, Center for Primary Care and Public Health (Unisanté), University of Lausanne, Lausanne, Switzerland.
Background: Health authorities worldwide have invested in digital technologies to establish robust information exchange systems for improving the safety and efficiency of medication management. Nevertheless, inaccurate medication lists and information gaps are common, particularly during care transitions, leading to avoidable harm, inefficiencies, and increased costs. Besides fragmented health care processes, the inconsistent incorporation of patient-driven changes contributes to these problems.
View Article and Find Full Text PDFComparison of inductively coupled plasma mass spectrometry and molybdenum blue colorimetry for total phosphorus determination in freshwater invertebrates.
PLoS One
January 2025
Department of Biology, Middlebury College, Middlebury, Vermont, United States of America.
Molybdenum blue colorimetry (MBC) is the dominant, well-established method used for determining total P in environmental media, including in organismal tissues. However, other elemental methods for P determination are available, including inductively coupled plasma mass spectrometry (ICP-MS). Given the extensive literature using MBC to determine P in organismal samples, it is important to assess P analyses by ICP-MS and MBC to ensure that the two methods produce comparable data.
View Article and Find Full Text PDFAcceptability and Determinants of Opportunistic Screening for Breast Cancer in Indian Women.
Asian Pac J Cancer Prev
January 2025
Department of General Surgery AIIMS Bhopal, India.
Background: Screening for breast cancer has been effective in decreasing mortality. Mammography is not readily available in resource-limited countries like India. Annual clinical breast examination has been demonstrated to be as effective as biennial mammography in reducing mortality with much less cost.
View Article and Find Full Text PDFInavolisib: First Approval.
Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Inavolisib (Itovebi) is an orally administered, phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitor being developed by Genentech, a member of the Roche group, for the treatment of solid tumours. On 10 October 2024, inavolisib received its first approval in the USA in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. In the EU and other countries worldwide, regulatory review of inavolisib is currently underway.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!